What is William Blair’s Estimate for Merus FY2027 Earnings?

Merus N.V. (NASDAQ:MRUS) – William Blair issued their FY2027 earnings per share estimates for Merus in a report released on Monday, September 29th. William Blair analyst M. Phipps anticipates that the biotechnology company will post earnings per share of ($3.62) for the year. William Blair currently has a “Hold” rating on the stock. The consensus estimate for Merus’ current full-year earnings is ($3.85) per share. William Blair also issued estimates for Merus’ FY2028 earnings at ($3.36) EPS.

Merus (NASDAQ:MRUS) last released its quarterly earnings results on Tuesday, August 5th. The biotechnology company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($1.17) by ($1.06). The company had revenue of $8.83 million for the quarter, compared to analyst estimates of $9.77 million. Merus had a negative return on equity of 50.28% and a negative net margin of 685.64%.

A number of other equities research analysts have also weighed in on MRUS. Guggenheim reaffirmed a “neutral” rating and set a $97.00 price target (down from $109.00) on shares of Merus in a report on Tuesday. HC Wainwright downgraded Merus from a “buy” rating to a “neutral” rating and lowered their target price for the company from $135.00 to $97.00 in a research note on Monday. Barclays reaffirmed an “equal weight” rating and set a $97.00 target price (down from $112.00) on shares of Merus in a research report on Tuesday. Canaccord Genuity Group downgraded Merus from a “buy” rating to a “hold” rating and increased their price target for the company from $67.00 to $97.00 in a report on Monday. Finally, BMO Capital Markets lowered Merus from an “outperform” rating to a “hold” rating in a research note on Tuesday. Four investment analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $92.88.

Merus Price Performance

MRUS opened at $94.15 on Wednesday. The firm’s 50 day moving average is $68.37 and its 200-day moving average is $55.38. Merus has a 52-week low of $33.19 and a 52-week high of $94.56. The firm has a market capitalization of $7.12 billion, a P/E ratio of -17.12 and a beta of 1.26.

Insider Transactions at Merus

In other Merus news, COO Peter B. Silverman sold 25,000 shares of the stock in a transaction that occurred on Thursday, July 17th. The stock was sold at an average price of $60.00, for a total transaction of $1,500,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders sold a total of 48,500 shares of company stock worth $2,792,500 in the last 90 days. Corporate insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On Merus

Several institutional investors and hedge funds have recently made changes to their positions in MRUS. Paradigm Biocapital Advisors LP boosted its holdings in Merus by 99.4% in the first quarter. Paradigm Biocapital Advisors LP now owns 3,369,699 shares of the biotechnology company’s stock worth $141,831,000 after purchasing an additional 1,679,777 shares during the period. Wellington Management Group LLP lifted its position in shares of Merus by 34.9% in the 1st quarter. Wellington Management Group LLP now owns 4,718,172 shares of the biotechnology company’s stock worth $198,588,000 after buying an additional 1,220,519 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of Merus by 1,007.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,133,857 shares of the biotechnology company’s stock valued at $59,641,000 after buying an additional 1,031,457 shares during the period. Adage Capital Partners GP L.L.C. acquired a new position in shares of Merus in the 2nd quarter valued at about $43,837,000. Finally, Westfield Capital Management Co. LP grew its position in shares of Merus by 36.0% during the 2nd quarter. Westfield Capital Management Co. LP now owns 2,042,388 shares of the biotechnology company’s stock valued at $107,430,000 after buying an additional 541,168 shares during the last quarter. 96.14% of the stock is owned by institutional investors and hedge funds.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.